SGLT2 Inhibitors (e.g., Dapagliflozin)

Treatment for Dilated Cardiomyopathy

Effectiveness
92%
Safety Score
65%
Clinical Trials
25
Participants
25K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
MethπŸ’€
Cigarettes🚬
Chemo☒️
Alcohol🍺
MorphineπŸ’Š
AntibioticsπŸ’‰
TylenolπŸ’Š
ExerciseπŸƒ
WaterπŸ’§
65
DangerousModerateSafe
Treatment Details
0
SGLT2 Inhibitors (e.g., Dapagliflozin) Outcomes

for Dilated Cardiomyopathy

Efficacy Outcomes
Overall Effectiveness
+92%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov